

Members Obtain Free CE Credits from JCP Articles!



SGLT2 Inhibitors' Cardiovascular Benefits in Individuals Without Diabetes, Heart Failure, and/or Chronic Kidney Disease: A Systematic Review

December 2023 – *The Journal of Clinical Pharmacology* (JCP)

Why is this article important to you?

This activity will expand learner knowledge on the cardiovascular benefits of sodium-glucose cotransporter-2 for its role from emerging evidence-based findings. Following the completion of this activity, learners will be able to explain how guideline-based meta-analyses outcomes can be interpreted for treatment advancements in cardiovascular diseases. Learners will enhance their knowledge on candidate guideline recommendation/s from the release of the 2022 AHA/American College of



Cardiology/Heart Failure Society of America guideline for managing Heart Failure. This activity will also cover the latest clinical findings on the effects of new SGLT2 inhibitors such as ertugliflozin, licogliflozin (LIK066), henagliflozin, bexagliflozin, and sotagliflozin on the Stage A Heart Failure and Metabolic Syndrome Outcomes in individuals without DM, HF, and/or CKD.

ACPE Accreditation Statement

The American College of Clinical Pharmacology® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

UAN: 0665-0000-23-037-H01-P – ACPE 1 Contact Hours

Activity Type: Knowledge-based **Format:** Home-study **Target Audience:** 'P'



ACCME Accreditation Statement

The American College of Clinical Pharmacology® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

ACCME Designation Statement

The Accreditation Council for Continuing Medical Education designates this journal CE activity for 1 *AMA PRA Category 1™* credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Target Audience

Interprofessional team of Physicians, Pharmacists, PhDs, Nurse Practitioners and Physician Assistants interested in expanding their knowledge on the cardiovascular benefits of sodium-glucose cotransporter-2 in emerging evidence-based findings.

Learning Objectives

After completing this activity, the learner will be able to:

1. Explain how guideline-based meta-analyses outcomes can be interpreted for treatment advancements in cardiovascular diseases;
2. Interpret candidate guideline recommendation/s from the release of the 2022 AHA/American College of Cardiology/Heart Failure Society of America guideline for managing Heart Failure;
3. Discuss the latest clinical findings on the effects of new SGLT2 inhibitors such as ertugliflozin, licogliflozin (LIK066), henagliflozin, bexagliflozin, and sotagliflozin on the Stage A Heart Failure and Metabolic Syndrome Outcomes in individuals without DM, HF, and/or CKD;

4. Describe the prevention role, safety framework and the adverse effects of sodium-glucose cotransporter-2 medications.

Requirements to Receive Credit

In order to receive continuing medical education (CME) or continuing pharmacy education (CPE) credit, the learner must register for the educational activity, study the provided journal article, complete the online learning Self-assessment Post-test as well as the online course Evaluation and CME/CPE Certificate. Credits and CME/CPE Certificates must be claimed within thirty (30) days of completing the article, Post-test and Evaluation. Contact CE@ACCP1.org with any questions.

Disclosures:

Article Selection: Joseph Bertino, PharmD, FCP, FCCP, Editor-in-Chief, JCP and Owner, Bertino Consulting Inc, selected the article for this course and has nothing to disclose.

Planner: Vatsalya Vatsalya, MD, PgD, MSc, MS, FRSM, Assistant Professor of Medicine, Univ of Louisville, Robley Rex VA Medical Ctr, planned the continuing education documentation for this course and has nothing to disclose.

CE Reviewer: Jesmin Lohy Das, BPharm, PhD, Assistant Principal Scientist, Merck, served as the CE Reviewer and all of the relevant financial relationships listed for this individual have been mitigated.

Schedule & Fees

JCP monthly Journal CE articles are generally released on the 1st or 2nd Tuesday of each month. They are priced in packages of January to December for each year. Packages are available at no cost to ACCP Members and \$75/calendar year to Non-members. Once you register, you have access to all of the Journal CE articles for the calendar year.

Acknowledgement of Financial Support

No financial support was received for this educational activity.

Home Study Initial Release and Expiration Dates

Date of Issuance: 12/1/2023

Expiration Date: 12/1/2026

Online Location:

<https://ce.accp1.org/products/2023-accp-journal-of-clinical-pharmacology-journal-ce-monthly-ce-offerings?token=WwOfO6X/XONcCWLl9ZRCLg==>